| 1. |
|
|
| 2. |
|
|
| 3. |
- Belfrage, Anna Karin, 1977-, et al.
(författare)
-
Palladium-Catalyzed Carbonylation of Aryl Iodides with Sulfinamides
- 2015
-
Ingår i: European Journal of Organic Chemistry. - : Wiley. - 1434-193X .- 1099-0690. ; :32, s. 7069-7074
-
Tidskriftsartikel (refereegranskat)abstract
- A facile palladium(0)-catalyzed carbonylative protocol for the generation of new acyl-sulfinamides in moderate to good yields is described. Aliphatic and aromatic sulfinamides were exploited as hitherto unexplored nucleophiles in carbonylation chemistry, with use of CO gas generated ex situ from Mo(CO)6 in a sealed two-chamber system. Both electron-poor and electron-rich (hetero)aryl iodides were employed as electrophiles. The two-chamber system and the use of an inorganic base were essential for efficacious synthesis of acyl-sulfinamide products. Finally, it was demonstrated that a one-pot (or single-vial) synthesis of acyl-sulfinamides was feasible under CO at balloon pressure in the presence of Cs2CO3 as base.
|
|
| 4. |
- Nandi, Ganesh C., et al.
(författare)
-
Pd-catalyzed C-N coupling of vinylbromides and sulfonimidamides : a facile synthesis of N '-vinylsulfonimidamides
- 2015
-
Ingår i: RSC Advances. - : Royal Society of Chemistry (RSC). - 2046-2069. ; 5:76, s. 62084-62090
-
Tidskriftsartikel (refereegranskat)abstract
- N'-Vinyl sulfonimidamides have been synthesized through a Pd-catalyzed C-N cross coupling between the N'-(imine nitrogen) of N'-deprotected sulfonimidamides and vinyl bromides. The hitherto unreported products were obtained in moderate to excellent yield, and the C-C double bond geometry of the vinylic substrates were retained during the course of reaction. Single crystal X-ray crystallographic analysis confirmed the product structure. Furthermore, we demonstrate that the formed N'-vinyl sulfonimidamides could undergo hydrogenation with Pd-C/H-2 to provide N'-alkyl sulfonimidamides.
|
|
| 5. |
|
|
| 6. |
- Wakchaure, Prasad B., et al.
(författare)
-
Synthesis of enantiopure angiotensin II type 2 receptor [AT(2)R] antagonist EMA401
- 2015
-
Ingår i: Tetrahedron. - : Elsevier BV. - 0040-4020 .- 1464-5416. ; 71:38, s. 6881-6887
-
Tidskriftsartikel (refereegranskat)abstract
- We report a facile synthesis of the angiotensin II type 2 receptor antagonist EMA401, which recently passed phase II clinical trials, in high overall yield. The synthesis of the key phenylalanine intermediate involved the formation of an a-nitro cinnamic ester and its reduction followed by a Pictet-Spengler cyclization, which furnished the tetrahydroisoquinoline core structure. Next, EMA401 was separated from its enantiomer EMA402 by four recrystalizations of a diastereomeric salt in 98% ee. All steps were performed on gram scale with emphasis on avoiding column purification and using readily available low cost starting materials and reagents.
|
|
| 7. |
|
|
| 8. |
- Zhang, Si Min, et al.
(författare)
-
NUDT15-mediated hydrolysis limits the efficacy of anti-HCMV drug ganciclovir
- 2021
-
Ingår i: Cell Chemical Biology. - : Elsevier BV. - 2451-9456 .- 2451-9448. ; 28:12, s. 1693-1702
-
Tidskriftsartikel (refereegranskat)abstract
- Ganciclovir (GCV) is the first-line therapy against human cytomegalovirus (HCMV), a widespread infection that is particularly dangerous for immunodeficient individuals. Closely resembling deoxyguanosine triphosphate, the tri-phosphorylated metabolite of GCV (GCV-TP) is preferentially incorporated by the viral DNA polymerase, thereby terminating chain extension and, eventually, viral replication. However, the treatment outcome of GCV varies greatly among individuals, therefore warranting better understanding of its metabolism. Here we show that NUDT15, a Nudix hydrolase known to metabolize thiopurine triphosphates, can similarly hydrolyze GCV-TP through biochemical studies and co-crystallization of the NUDT15/GCV-TP complex. More critically, GCV efficacy was potentiated in HCMV-infected cells following NUDT15 depletion by RNAi or inhibition by an in-house-developed, nanomolar NUDT15 inhibitor, TH8321, suggesting that pharmacological targeting of NUDT15 is a possible avenue to improve existing anti-HCMV regimens. Collectively, the data further implicate NUDT15 as a broad-spectrum metabolic regulator of nucleoside analog therapeutics, such as thiopurines and GCV.
|
|
